ALXO Q3 2022 Earnings — ALX Oncology Holdings Inc. Revenue & Financial Results | Market Cap Arena

ALXOALX Oncology Holdings Inc.

$113M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$37M

Net Income

-$35M

EPS (Diluted)

$-0.87

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$318M

Total Liabilities

$31M

Stockholders' Equity

$287M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$37M	-$25M	-49.3%
Net Income	-$35M	-$25M	-43.8%